Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Marguerite Vignon, Valérie Lauwers‐Cancès et al.|Blood|2022Cited by 25
Bcl-2 protein level in blood of patients with acute myeloid leukaemiaBruno Baudin, Michel Vaubourdolle, Abdelkrim Tahraoui et al.|Unknown|2008Cited by 0